TerraPower

TerraPower Isotopes (Actinium-225)

Active

Medical-isotope business producing actinium-225 (Ac-225), a rare alpha-particle-emitting isotope used in targeted radiotherapeutics for cancers including prostate, breast, colon, and neuroendocrine cancers, melanoma, and lymphoma.

Latest update Sep 18, 2026

01

Current status

Producing Ac-225 at commercial scale via weekly production runs since October 2024, supplying pharmaceutical partners for radiopharmaceutical development and human clinical trials from its Everett, Washington facility. A second, larger cGMP facility (the Bellwether Laboratory in Philadelphia, $450M investment, 250,000 sq ft) broke ground May 6, 2026 and is intended to expand global Ac-225 capacity twentyfold, with production starting in 2029. TerraPower's isotopes page, re-verified September 18, 2026, still describes the Philadelphia plant as under construction with a twentyfold capacity increase. TerraPower Isotopes sources its thorium-229 feedstock from DOE contractor Isotek Systems at Oak Ridge; a new Isotek analytical lab opened August 21, 2026 speeds Th-229 delivery and supports the decay-based technique TerraPower uses to extract Ac-225.

02

Specifications3

Production Status
Commercial scale

weekly production runs since Oct. 2024

Philadelphia Facility Investment
$450M (Bellwether Laboratory, 250,000 sq ft)
Philadelphia Facility Production Start
2029

03

Upcoming milestones1

Announced next steps from TerraPower that mention TerraPower Isotopes (Actinium-225).

  1. 2029

    Bring Bellwether Laboratory (Philadelphia) online

    Complete construction of the $450M, 250,000-square-foot Bellwether Laboratory in Philadelphia's Bellwether District (groundbreaking May 6, 2026) and begin cGMP actinium-225 production there, expanding TerraPower Isotopes' global Ac-225 capacity twentyfold alongside its existing Everett, Washington site. Not yet online as of September 18, 2026; TerraPower's isotopes page still describes the Philadelphia plant as under construction with a twentyfold capacity increase, and no delay to the 2029 production-start target has been reported.

04

More from TerraPower2

05

More in Nuclear Fission